Key result
Flecainide reduces proarrhythmic events without increasing mortality in supraventricular arrhythmias lacking ventricular damage.
Why the study?
Is flecainide safe regarding mortality and proarrhythmic events in patients with supraventricular arrhythmias and no structural ventricular damage?
Population
122 prospective studies pooling 4,811 patients on flecainide with supraventricular arrhythmias and no…
Comparison
Flecainide vs Placebo or other antiarrhythmics
Design
Meta-analysis
Follow-up
Total exposure time 2015 patient years
Authors
Loading...
Affirms flecainide safety for supraventricular arrhythmias without ventricular damage; reinforces prior trial evidence for clinical use.
Meta-Analysis (n=4,811)
Is flecainide safe regarding mortality and proarrhythmic events in patients with supraventricular arrhythmias and no structural ventricular damage?
p-value: p=0.46
Flecainide appears safe for the treatment of supraventricular arrhythmias in patients without structural left ventricular damage, with no significant increase in mortality compared to controls.
Martin Wehling (2011) conducted a meta-analysis in Supraventricular arrhythmias (n=4,811). Flecainide vs. Placebo or other antiarrhythmics was evaluated on Total mortality (p=0.46). Flecainide use in patients with supraventricular arrhythmias and no ventricular damage was safe, with a total mortality of 0.166% (P=0.46 vs controls) and fewer proarrhythmic events (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: